REGENXBIO Inc. $RGNX Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. boosted its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 64.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,160,380 shares of the biotechnology company’s stock after acquiring an additional 454,977 shares during the quarter. Assenagon Asset Management S.A. owned 2.29% of REGENXBIO worth $16,709,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. AQR Capital Management LLC lifted its position in shares of REGENXBIO by 2,247.7% during the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock worth $4,437,000 after purchasing an additional 594,161 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of REGENXBIO by 151.1% in the first quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company’s stock valued at $2,961,000 after purchasing an additional 249,156 shares during the period. Geode Capital Management LLC grew its holdings in shares of REGENXBIO by 1.9% in the second quarter. Geode Capital Management LLC now owns 1,128,521 shares of the biotechnology company’s stock valued at $9,267,000 after purchasing an additional 21,575 shares in the last quarter. Intech Investment Management LLC increased its stake in REGENXBIO by 26.5% during the 2nd quarter. Intech Investment Management LLC now owns 27,100 shares of the biotechnology company’s stock worth $222,000 after buying an additional 5,682 shares during the period. Finally, Rockefeller Capital Management L.P. purchased a new stake in REGENXBIO during the 2nd quarter worth approximately $220,000. 88.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at REGENXBIO

In related news, insider Steve Pakola sold 5,124 shares of the stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $10.35, for a total value of $53,033.40. Following the transaction, the insider directly owned 247,926 shares of the company’s stock, valued at $2,566,034.10. This trade represents a 2.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 12.79% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have commented on RGNX. UBS Group reissued an “overweight” rating and issued a $18.00 price target on shares of REGENXBIO in a research report on Tuesday, February 10th. The Goldman Sachs Group reduced their price objective on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Chardan Capital decreased their target price on REGENXBIO from $52.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Finally, HC Wainwright cut their price target on REGENXBIO from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, REGENXBIO has an average rating of “Moderate Buy” and an average target price of $27.50.

REGENXBIO Stock Down 2.4%

RGNX stock opened at $8.26 on Friday. The business has a 50 day moving average price of $9.88 and a 200 day moving average price of $11.37. The stock has a market cap of $426.30 million, a price-to-earnings ratio of -2.20 and a beta of 1.08. REGENXBIO Inc. has a fifty-two week low of $5.03 and a fifty-two week high of $16.19.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Thursday, March 5th. The biotechnology company reported ($1.30) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.29). REGENXBIO had a negative net margin of 113.75% and a negative return on equity of 103.12%. The company had revenue of $30.34 million during the quarter, compared to analysts’ expectations of $45.48 million. As a group, sell-side analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current year.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.